Novo Nordisk slides further on US competition, new CEO concerns
By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN (Reuters) -Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs in the United States, a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker’s value. Novo …
Novo Nordisk slides further on US competition, new CEO concerns Read More »









